The efficacy of Tranexamic acid in reducing postoperative blood loss in arthroscopic anterior cruciate ligament reconstruction

The efficacy of Tranexamic acid in reducing postoperative blood loss in arthroscopic anterior cruciate ligament reconstruction : A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220119007

Enrollment

Registered

2022-01-19

Start date

2021-05-17

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients who underwent arthroscopic ACL reconstruction tranexamic acid , ACL reconstruction

Interventions

Tranexamic acid (250 mg/5 mL) 10 mg/kg intravenous (preoperative 10 min)

Placebo Comparator Drug

TXA group

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients who underwent arthroscopic ACL reconstruction

Exclusion criteria

Exclusion criteria: U/D Bleeding disorder , ischemic heart disease , malignancy Hx. DVT / Pulmonary embolism preoperative anticoagulation therapy abnormal coagulation profile renal disorder or insufficiency, allergy to local anesthetics/TXA revision case

Design outcomes

Primary

Measure	Time frame
postoperative blood loss 24 hour after end of the intervention % chance of Hct preoperativep to postoperative	—

Secondary

Measure	Time frame
Hemathrosis 2 wk after end of the intervention grading of hemathrosis	—

Countries

Thailand

Contacts

Public Contactthanatja kittijarukajon

orthopedic department

hihinatja@hotmail.com0955174953

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026